Literature DB >> 1699945

Sacrosine- and prolinedithiocarbamate pretreatment increases the therapeutic efficacy of doxorubicin, methotrexate, teniposide, mitoxantrone or cyclohexylchloroethylnitrosourea in leukemia L1210.

H Osswald1, N Frank.   

Abstract

The influence of different doses of the hydrophilic sarcosine- or prolinedithiocarbamate on the chemotherapeutic efficacy of doxorubicin, teniposide, methotrexate, mitoxantrone or cyclohexylchlorethylnitrosourea was evaluated in female B6D2F1 mice bearing leukemia L1210, implanted intraperitoneally. The simultaneous administration of these dithiocarbamates and the drugs used induced no increase of the therapeutic efficacy of the combinations compared to the corresponding dose of the drug and simultaneously applied saline. The results indicate that the subcutaneous pretreatment with sarcosine- or prolinedithiocarbamate increased the therapeutic efficacy of the drugs used compared to the corresponding monotherapy, in which saline was applied in the same interval as the dithiocarbamate and the antineoplastic agents. Sarcosine- or prolinedithiocarbamate applied alone did not influence leukemia L1210. The increase of the efficacy of the drugs used by sequential combination with sarcosine- or prolinedithiocarbamate seems to be influenced predominantly by diminishing the toxicity as well as by modulating the chemotherapeutic action.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699945     DOI: 10.1007/bf01612992

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  16 in total

1.  Decrease in mouse lung and liver glutathione peroxidase activity and potentiation of the lethal effects of ozone and paraquat by the superoxide dismutase inhibitor diethyldithiocarbamate.

Authors:  B D Goldstein; M G Rozen; J C Quintavalla; M A Amoruso
Journal:  Biochem Pharmacol       Date:  1979       Impact factor: 5.858

2.  Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.

Authors:  D L Bodenner; P C Dedon; P C Keng; J C Katz; R F Borch
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

3.  Effect of diethyldithiocarbamate rescue on tumor response to cis-platinum in a rat model.

Authors:  R F Borch; J C Katz; P H Lieder; M E Pleasants
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

4.  Nickel poisoning. VIII. Dithiocarb: a new therapeutic agent for persons exposed to nickel carbonyl.

Authors:  F W SUNDERMAN; F W SUNDERMAN
Journal:  Am J Med Sci       Date:  1958-07       Impact factor: 2.378

5.  The oxidation of alpha-beta unsaturated aldehydic products of lipid peroxidation by rat liver aldehyde dehydrogenases.

Authors:  D Y Mitchell; D R Petersen
Journal:  Toxicol Appl Pharmacol       Date:  1987-03-15       Impact factor: 4.219

6.  Effects of diethyldithiocarbamate and nickel chloride on glutathione and trace metal concentrations in rat liver.

Authors:  F W Sunderman; O Zaharia; M C Reid; J F Belliveau; G P O'Leary; H Griffin
Journal:  Toxicology       Date:  1984-07       Impact factor: 4.221

7.  Protective effects of glutathione on diethyldithiocarbamate (DDC) cytotoxicity: a possible mechanism.

Authors:  L D Trombetta; M Toulon; I S Jamall
Journal:  Toxicol Appl Pharmacol       Date:  1988-03-30       Impact factor: 4.219

8.  Mechanisms of diethyldithiocarbamate-induced loss of cytochrome P-450 from rat liver.

Authors:  G E Miller; M A Zemaitis; F E Greene
Journal:  Biochem Pharmacol       Date:  1983-08-15       Impact factor: 5.858

9.  Inhibition of HIV progression by dithiocarb. German DTC Study Group.

Authors:  E C Reisinger; P Kern; M Ernst; P Bock; H D Flad; M Dietrich
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

10.  Effect of diethyldithiocarbamate on toxicity of doxorubicin, cyclophosphamide and cis-diamminedichloroplatinum (II) on mice haemopoietic progenitor cells.

Authors:  I M Pannacciulli; R A Lerza; G V Bogliolo; M P Mencoboni; A G Saviane
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.